11/18
08:08 am
ctnm
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain [Yahoo! Finance]
Medium
Report
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain [Yahoo! Finance]
11/18
08:05 am
ctnm
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Medium
Report
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
11/13
04:05 pm
ctnm
Contineum Therapeutics to Attend Upcoming Investor Conferences
Medium
Report
Contineum Therapeutics to Attend Upcoming Investor Conferences
11/7
12:32 pm
ctnm
Contineum Therapeutics, Inc. (NASDAQ: CTNM) had its price target lowered by analysts at Royal Bank of Canada from $32.00 to $31.00. They now have an "outperform" rating on the stock.
Medium
Report
Contineum Therapeutics, Inc. (NASDAQ: CTNM) had its price target lowered by analysts at Royal Bank of Canada from $32.00 to $31.00. They now have an "outperform" rating on the stock.
11/6
05:06 pm
ctnm
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/6
04:05 pm
ctnm
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
10/23
07:56 am
ctnm
Contineum Therapeutics, Inc. (NASDAQ: CTNM) was upgraded by analysts at Baird R W to a "strong-buy" rating.
Low
Report
Contineum Therapeutics, Inc. (NASDAQ: CTNM) was upgraded by analysts at Baird R W to a "strong-buy" rating.
10/22
07:39 am
ctnm
Contineum Therapeutics, Inc. (NASDAQ: CTNM) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $32.00 price target on the stock.
Low
Report
Contineum Therapeutics, Inc. (NASDAQ: CTNM) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $32.00 price target on the stock.
10/4
08:16 am
ctnm
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28% [Yahoo! Finance]
Medium
Report
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28% [Yahoo! Finance]
8/28
04:05 pm
ctnm
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
Low
Report
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences